Head to head
Semaglutide against 5-Amino-1MQ
5-Amino-1MQ is sold to people who have read about GLP-1 drugs and want something oral and unregulated. One has phase 3 trials and an approval; the other has animal work and no human trial, and that gap is the whole comparison.
Column A
SemaglutideSemaglutide (GLP-1 receptor agonist)
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Column B
5-Amino-1MQ5-Amino-1-Methylquinolinium (NNMT inhibitor)
An experimental small-molecule enzyme inhibitor studied in animals for fat metabolism and muscle, popular on longevity resources.
Side by side, on the facts we can check
| Attribute | Semaglutide | 5-Amino-1MQ |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management) | Not FDA-approved; experimental |
| Half-life | ~7 days | Short |
| Molecular weight | 4,113.6 Da | 159.2 Da |
| Mechanism | Activates the GLP-1 receptor, increasing insulin secretion when glucose is elevated, suppressing glucagon, slowing gastric emptying, and acting on hypothalamic appetite centers to reduce food intake. | Inhibits nicotinamide N-methyltransferase (NNMT), altering fat cell energy metabolism and preserving cellular NAD-related pathways. |
| Human studies cited | 5 | 0 |
| Legal status, US | FDA-approved, prescription only | Not approved; research use only |
Frequently asked questions
What is the difference between Semaglutide and 5-Amino-1MQ?
Semaglutide: A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction. 5-Amino-1MQ: An experimental small-molecule enzyme inhibitor studied in animals for fat metabolism and muscle, popular on longevity resources.
Which has stronger research evidence, Semaglutide or 5-Amino-1MQ?
This database does not grade compounds. It counts what was run in people: 5 of the 5 studies cited on the Semaglutide profile were human work, against 0 of 2 for 5-Amino-1MQ. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Semaglutide and 5-Amino-1MQ FDA-approved?
Semaglutide: FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management). 5-Amino-1MQ: Not FDA-approved; experimental.
Related posts
Blog articles that cover Semaglutide or 5-Amino-1MQ, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Longevity / Sep 8, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Metabolic / Sep 8, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.